MA37676B1 - Nouveau promédicament de rebamipide, son procédé de fabrication et son utilisation - Google Patents
Nouveau promédicament de rebamipide, son procédé de fabrication et son utilisationInfo
- Publication number
- MA37676B1 MA37676B1 MA37676A MA37676A MA37676B1 MA 37676 B1 MA37676 B1 MA 37676B1 MA 37676 A MA37676 A MA 37676A MA 37676 A MA37676 A MA 37676A MA 37676 B1 MA37676 B1 MA 37676B1
- Authority
- MA
- Morocco
- Prior art keywords
- rebamipid
- prodrug
- manufacturing process
- manufacture
- new prodrug
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
Abstract
La présente invention concerne un nouveau promédicament de rebamipide, son procédé de fabrication et son utilisation, et, de façon plus spécifique, un nouveau promédicament de rebamipide, son procédé de fabrication et une composition pharmaceutique le contenant comme principe actif. Le nouveau promédicament de rebamipide selon la présente invention a une vitesse d'absorption dans le corps d'approximativement 25 fois la vitesse d'absorption du rebamipide, et ainsi peut être utilisé de façon efficace, à la place du rebamipide, dans la prévention ou le traitement de l'ulcère gastrique, de la gastrite aiguë et chronique, du syndrome de sécheresse oculaire, du cancer, de l'arthrose, de la polyarthrite rhumatoïde ou de l'obésité.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20120068394 | 2012-06-26 | ||
| PCT/KR2013/005622 WO2014003424A1 (fr) | 2012-06-26 | 2013-06-26 | Nouveau promédicament de rebamipide, son procédé de fabrication et son utilisation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA37676A1 MA37676A1 (fr) | 2016-10-31 |
| MA37676B1 true MA37676B1 (fr) | 2017-07-31 |
Family
ID=49783488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37676A MA37676B1 (fr) | 2012-06-26 | 2013-06-26 | Nouveau promédicament de rebamipide, son procédé de fabrication et son utilisation |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US11420963B2 (fr) |
| EP (1) | EP2865669B1 (fr) |
| JP (1) | JP6032451B2 (fr) |
| KR (1) | KR101452277B1 (fr) |
| CN (1) | CN104662004B (fr) |
| AP (1) | AP2015008233A0 (fr) |
| AR (1) | AR097226A1 (fr) |
| AU (1) | AU2013281442B2 (fr) |
| BR (1) | BR112014032627A8 (fr) |
| CA (1) | CA2877853C (fr) |
| CL (1) | CL2014003496A1 (fr) |
| CO (1) | CO7240352A2 (fr) |
| ES (1) | ES2875863T3 (fr) |
| IL (1) | IL236479A0 (fr) |
| MA (1) | MA37676B1 (fr) |
| MX (1) | MX2015000023A (fr) |
| NZ (1) | NZ704023A (fr) |
| PE (2) | PE20150904A1 (fr) |
| PH (1) | PH12015500172B1 (fr) |
| RU (1) | RU2612509C2 (fr) |
| SA (1) | SA113340675B1 (fr) |
| SG (1) | SG11201408711PA (fr) |
| TW (1) | TWI483727B (fr) |
| UA (1) | UA113990C2 (fr) |
| UY (1) | UY34882A (fr) |
| WO (1) | WO2014003424A1 (fr) |
| ZA (1) | ZA201500450B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101692578B1 (ko) * | 2013-04-18 | 2017-01-03 | 삼진제약주식회사 | 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물 |
| WO2016108319A1 (fr) * | 2015-01-02 | 2016-07-07 | 삼진제약 주식회사 | Nouveau sel de promédicament du rébamipide et son utilisation |
| KR20170094584A (ko) * | 2016-02-11 | 2017-08-21 | 삼진제약주식회사 | 레바미피드 전구체를 포함하는 면역질환 및 대사성질환의 예방 또는 치료를 위한 경구투여용 약제학적 조성물 |
| KR102190019B1 (ko) * | 2018-10-23 | 2020-12-15 | 삼진제약주식회사 | 쇼그렌 증후군 예방 또는 치료용 조성물 |
| CN111595985B (zh) * | 2020-07-09 | 2022-03-29 | 苏州正济药业有限公司 | 一种用hplc测定瑞巴派特有关物质的分析方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI80022C (fi) * | 1982-07-05 | 1990-04-10 | Otsuka Pharma Co Ltd | Foerfarande foer framstaellning av ett nytt, terapeutiskt anvaendbart karbostyrilderivat. |
| JPS6019767A (ja) | 1983-07-11 | 1985-01-31 | Otsuka Pharmaceut Co Ltd | カルボスチリル誘導体を有効成分とする抗潰瘍剤 |
| JP3621463B2 (ja) | 1995-04-26 | 2005-02-16 | 大塚製薬株式会社 | カルボスチリル誘導体ビスマス塩 |
| KR100669823B1 (ko) | 2001-02-20 | 2007-01-17 | 경동제약 주식회사 | 2-(4-클로로벤조일아미노)-3-[2(1ｈ)-퀴놀리논-4-일]프로피온산의 제조방법 및 그 중간체 |
| EP1336602A1 (fr) | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Prodrogues nitrées capable de libérer du monoxyde d'azote de manière controlée et sélective ainsi que leur utilisation pour la prévention et le traitement de maladies inflammatoires, ischémiques et proliferatives |
| KR20040104020A (ko) | 2003-06-02 | 2004-12-10 | 진양제약주식회사 | 신규 레바미피드 리지네이트와 레바미피드 아르기니네이트및 이 신규 레바미피드 리지네이트와 레바미피드아르기니네이트를 유효성분으로 함유하는 약학적 제제 |
| TWI363626B (en) * | 2004-11-15 | 2012-05-11 | Otsuka Pharma Co Ltd | Aqueous ophthalmic suspension of crystalline rebamipide |
| WO2006059781A1 (fr) * | 2004-12-01 | 2006-06-08 | Otsuka Pharmaceutical Co., Ltd. | Procédé amélioré de synthèse du rebamipide |
| JP2008105970A (ja) | 2006-10-24 | 2008-05-08 | Ohara Yakuhin Kogyo Kk | ジヒドロキノリン誘導体の製造方法及びその中間体 |
| WO2008074853A1 (fr) | 2006-12-21 | 2008-06-26 | Novartis Ag | Solution ophtalmique de rebamipide |
| KR101032600B1 (ko) | 2008-08-11 | 2011-05-06 | 동우신테크 주식회사 | 고순도 레바미피드의 제조방법 |
| KR101182114B1 (ko) * | 2010-03-05 | 2012-09-12 | 한림제약(주) | 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물 |
| CN102174015B (zh) * | 2011-03-07 | 2013-10-16 | 江西同和药业有限责任公司 | 瑞巴派特的精制方法 |
-
2013
- 2013-06-24 SA SA113340675A patent/SA113340675B1/ar unknown
- 2013-06-26 CA CA2877853A patent/CA2877853C/fr active Active
- 2013-06-26 ES ES13809037T patent/ES2875863T3/es active Active
- 2013-06-26 PE PE2014002534A patent/PE20150904A1/es not_active Application Discontinuation
- 2013-06-26 EP EP13809037.8A patent/EP2865669B1/fr active Active
- 2013-06-26 KR KR1020130073535A patent/KR101452277B1/ko active IP Right Grant
- 2013-06-26 RU RU2015102043A patent/RU2612509C2/ru active
- 2013-06-26 AU AU2013281442A patent/AU2013281442B2/en active Active
- 2013-06-26 MA MA37676A patent/MA37676B1/fr unknown
- 2013-06-26 UA UAA201500494A patent/UA113990C2/uk unknown
- 2013-06-26 NZ NZ704023A patent/NZ704023A/en not_active IP Right Cessation
- 2013-06-26 WO PCT/KR2013/005622 patent/WO2014003424A1/fr active Application Filing
- 2013-06-26 PE PE2016000265A patent/PE20160285A1/es unknown
- 2013-06-26 MX MX2015000023A patent/MX2015000023A/es unknown
- 2013-06-26 UY UY0001034882A patent/UY34882A/es not_active Application Discontinuation
- 2013-06-26 BR BR112014032627A patent/BR112014032627A8/pt not_active Application Discontinuation
- 2013-06-26 JP JP2015520012A patent/JP6032451B2/ja active Active
- 2013-06-26 US US14/411,390 patent/US11420963B2/en active Active
- 2013-06-26 SG SG11201408711PA patent/SG11201408711PA/en unknown
- 2013-06-26 TW TW102122678A patent/TWI483727B/zh active
- 2013-06-26 AP AP2015008233A patent/AP2015008233A0/xx unknown
- 2013-06-26 AR ARP130102268A patent/AR097226A1/es unknown
- 2013-06-26 CN CN201380034373.4A patent/CN104662004B/zh active Active
-
2014
- 2014-12-22 CL CL2014003496A patent/CL2014003496A1/es unknown
- 2014-12-25 IL IL236479A patent/IL236479A0/en unknown
-
2015
- 2015-01-22 ZA ZA2015/00450A patent/ZA201500450B/en unknown
- 2015-01-26 CO CO15014548A patent/CO7240352A2/es unknown
- 2015-01-26 PH PH12015500172A patent/PH12015500172B1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA37676A1 (fr) | Nouveau promédicament de rebamipide, son procédé de fabrication et son utilisation | |
| MA41013A (fr) | Compositions comprenant des souches bactériennes | |
| MA34248B1 (fr) | 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation | |
| MA39211B1 (fr) | Composés tricycliques comme agents anti-cancers | |
| EA201690153A1 (ru) | Замещенные бензофуранильные и бензоксазолильные соединения и их применения | |
| NZ702414A (en) | Compositions comprising zoledronic acid or related compounds for relieving inflammatory pain and related conditions | |
| EA201692271A1 (ru) | Терапевтически активные соединения и способы их применения | |
| EA201391668A1 (ru) | Способы лечения или предупреждения связанных с холестерином расстройств | |
| FR2985274B1 (fr) | Structures fibreuses comprenant des particules et leur procede de fabrication | |
| EA201501032A1 (ru) | Фармацевтическая композиция, способы лечения и ее применения | |
| EA201390409A1 (ru) | Составы с низкой дозой панкрелипазы и кишечно-растворимым покрытием | |
| MA38060A1 (fr) | Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisation | |
| EA201200519A1 (ru) | Стабилизированные жидкие и лиофилизированные композиции adamts13 | |
| MA41238B1 (fr) | Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit | |
| EA201691844A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
| FR3029790B1 (fr) | Microbille d'hydrogel de chitosane | |
| MX2018003975A (es) | Combinacion de glicosaminoglicanos y un agente antacido y sus composiciones. | |
| CA2929436C (fr) | Composes, composition pharmaceutique et methodes a utiliser dans le traitement de maladies inflammatoires | |
| MA38349A1 (fr) | Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3) | |
| MA39170A1 (fr) | Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer | |
| MX355330B (es) | Formas cristalinas de compuestos terapeuticos y sus usos. | |
| MA34724B1 (fr) | Nouvelle forme d'administration d'un inhibiteur de l'enképhalinase | |
| EA201790070A1 (ru) | Бифениламиды, содержащие модифицированные простые эфирные группы, в качестве ингибиторов hsp90 и стимуляторов hsp70 | |
| MA38253A1 (fr) | Compositions comprenant de la vortioxétine et du donépézil | |
| MA20150279A1 (fr) | (r)-nifuratel, son utilisation pour le traitement d'infections et synthèse de (r) et (s)-nifuratel |